Compugen Ltd
CGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$247.26M
Close$
$2.54
8.6% downside
Current Fair Value
8.6% downsideOvervalued by 8.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $247.26 Million |
|---|---|
| Enterprise Value | $251.46 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.38 |
| Beta | 2.78 |
| Outstanding Shares | 94,640,696 |
Return
| Return on Equity | 39.66% |
|---|---|
| Return on Assets | 25.43% |
| Return on Invested Capital | 29.76% |
Valuation & Multiples
| P/E Ratio | 6.97 |
|---|---|
| PEG | -152.21 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.4 |
| Enterprise Value to EBIT | 7.3 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$1.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
$1.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 123,900▲ Infinity% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 15.20%▲ 1.72% |
|---|---|
| Total Invested | $30.90M▲ 56.48% |
| Investors Holding | 81▲ 7.00% |
ESG Score
No data
About Compugen Ltd
CEO: Anat Cohen-Dayag Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immu...